A Comprehensive Cancer Program
Only Cancer Guardian combines the power of genomics with a team of oncology trained specialists and the latest in cancer navigation technology.
It’s Not Insurance, It’s Better.
Unlike health insurance, Cancer Guardian services require no deductibles, no co-pays, no denials, no waiting, and no additional out-of-pocket expense. It provides services not typically made available or covered by health plans, and you can take advantage of these services from Day 1 of membership.
Cancer Support Specialists
At any time, you have access to the Cancer Information Line to ask any cancer related questions, concerns, risk-mitigation strategies, or caregiving guidance. If diagnosed with cancer, you are provided with:
- A Dedicated Cancer Support Specialist
- Expert Pathology Review
- On-Site Nurse Advocate (one visit)
Advanced DNA Testing
Take preventative measures by understanding your genetic risk of cancer with the Hereditary Risk Screening Test. If you are diagnosed with cancer, fully-funded access to Comprehensive Genomic Profiling can help your doctor identify the most effective treatment options.
Cancer Navigation Technology
The cancer journey can be confusing and financially devastating. Cancer Guardian provides white-glove support through:
- Medical Records Platform
- Clinical Trial Explorer
- Financial Navigation
Cancer Guardian’s comprehensive program delivers support when you need it, and peace of mind when you don’t…
References
1. Lifetime Risk of Developing or Dying from Cancer Basic Facts. American Cancer Society, 2019.
2. Wamberg Genomic Advisors, Cancer Survey of 204 cancer patients and nonprofessional advocates. Survey Sampling International (SSI), 2018.
3. Unger, Joseph M., et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician and Patient Barriers to Cancer Clinical Trial Participation. JNCI J NATL Cancer Institute, 2019.
4. Family Reach. Annual Report 2016. Family Reach Foundation https://familyreachorg/wp-content/uploads/
2017/05/ frf_2016_annual_report_compressedpdf Accessed July 30, 2017.
5. CancerCare. Cancer Care Patient Access and Engagement Report. New York: CancerCare. 2016.
6. Manchanda, Ranjit, et al. Population based germline testing for primary cancer prevention. Oncotarget, 2018, Vol. 9 (No. 69), pp: 33062-33063
7. Waszak, Przemyslaw M. et al. The Spread of Medical Fake News in Social Media. Health Policy & Technology Review, Elsevier, 2018.
8. Stephen S. Raab, Dana M. Grzybicki, CA Cancer J. Clin. 2010 May-Jun,60(3): 139-65
9. Raab, Stephen S. MD, et al. Quality in Cancer Diagnosis. Cancer J. Clinical 2010
10. J. Unger, et al., Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician Barriers to Cancer Clinical Trial Participation, JNCI J Natl Cancer Inst 2019
11. The State of Cancer Care in America, 2014: A report by the American Society of Clinical Oncology. Journal of Oncology Practice, 2014; 10(2):120-122
12. Sun Life Stop-Loss Report, 2019. https://sunlife.showpad.com/share/
7SzmNmJJs1a6msorM0DZA
14. Measuring Health-Related Productivity Loss. https://ww.liebertpubl.com/doi/pdf/10.3322/caac.20068.
16. Wamberg Genomic Advisors Cancer Survey of 204 cancer patients and nonprofessional advocates fielded by Survey Sampling International (SSI), 2018. Available at: https://www.managedhealthcareexecutive.com/leukemia-and-lymphoma/
most-troubling-part-cancer-treatment-patients
